Research Article
Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation
Table 1
Baseline characteristics of the study population.
| Parameternumber of patients | |
| Demographic data | Age768 (years, mean (SD)) | 63.36 (10.71) [17-90] | (years) | 95 (12%) | Age 65-74 (years) | 271 (35%) | (years) | 340 (44%) | BMI567 (kg/m2, mean (SD)) | 29.46 (5.38) | Female: (%) | 297 (39%) | Type of procedure768:(%) | Ablation | 365 (47%) | Cardioversion | 403 (53%) | Type of AF768:(%) | AF paroxysmal | 287 (37%) | Clinical data:(%) | HF766 | 240 (31%) | NYHA I-II | 209 (87.1%) | NYHA III | 26 (10.8%) | NYHA IV | 5 (2.1%) | HT768 | 581 (75%) | DM767 | 179 (23%) | Stroke768 | 52 (6.8%) | Coronary disease768 | 506 (66%) | Biological aortic prosthesis768 | 19 (2.5%) | CHA2DS2-VASC score768 (mean (SD)) | 2.48 (1.53) | : (%) | 65 (8.6%) | : (%) | 154 (20%) | : (%) | 549 (71.4%) | HASBLED score768 (mean (SD)) | 1.58 (0.99) | Liver abnormal function767 | 110 (14%) | Renal abnormal function767 | 100 (13%) | Bleeding in anamnesis768 | 50 (6.5%) | Laboratory data (mean (SD))761 | Hemoglobin (g/dl) | 14.10 (1.54) | Creatinine (mg/dl) | 1.04 (0.31) | ml/min/1.73 m2 | 189 (25%) | Type of anticoagulation therapy768:(%) | NOAC | 523 (68%) | (i) Dabigatran | 240 (46%) | (ii) Rivaroxaban | 279 (53%) | (iii) Apixaban | 4 (0.7%) | VKA | 227 (30%) | OAC | 750 (98%) | Reduced NOAC | 54 (7%) | Heparin | 11 (1.5%) |
|
|
Abbreviations: AF: atrial fibrillation; BMI: body mass index; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HF: heart failure; HT: hypertension; NOAC: non-vitamin K antagonist oral anticoagulants; OAC: oral anticoagulation therapy; VKA: vitamin K antagonist.
|